InsidersTradesSigma
Follow the CYTOKINETICS, INCORPORATED share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €10.6bn. The latest transaction was filed on 30 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Sung Lee. All data is accessible without an account.
Analysts rate CYTOKINETICS, INCORPORATED Strong Buy (bullish), based on 20 analysts. Average price target: US$107.80.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
CYTOKINETICS, INCORPORATED is a biopharmaceutical company focused on developing treatments for muscle and heart diseases. It employs innovative approaches to enhance muscle function and physical performance.